KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Payables (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Payables for 4 consecutive years, with $10.8 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Payables fell 5.03% year-over-year to $10.8 million, compared with a TTM value of $10.8 million through Sep 2023, down 5.03%, and an annual FY2022 reading of $10.5 million, up 27.62% over the prior year.
  • Payables was $10.8 million for Q3 2023 at Ginkgo Bioworks Holdings, down from $13.6 million in the prior quarter.
  • Across five years, Payables topped out at $35.3 million in Q1 2022 and bottomed at $1.4 million in Q1 2021.
  • Average Payables over 4 years is $12.5 million, with a median of $10.8 million recorded in 2023.
  • The sharpest move saw Payables tumbled 42.3% in 2021, then soared 2379.71% in 2022.
  • Year by year, Payables stood at $14.2 million in 2020, then tumbled by 42.3% to $8.2 million in 2021, then increased by 27.62% to $10.5 million in 2022, then grew by 2.89% to $10.8 million in 2023.
  • Business Quant data shows Payables for DNA at $10.8 million in Q3 2023, $13.6 million in Q2 2023, and $21.6 million in Q1 2023.